Similar articles for PMID: 18413376

Year	Number of Results
1989	1
1992	1
1993	2
1995	1
1996	1
1997	2
1998	4
1999	5
2000	7
2001	3
2002	5
2003	13
2004	7
2005	6
2006	3
2007	9
2008	6
2009	9
2010	6
2011	7
2012	10
2013	5
2014	5
2015	2
2016	4
2017	8
2018	5
2019	2
2020	2
2021	11
2022	7
2023	4
2024	0

1

Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.

Rajendran JG, Gopal AK, Fisher DR, Durack LD, Gooley TA, Press OW. Rajendran JG, et al. J Nucl Med. 2008 May;49(5):837-44. doi: 10.2967/jnumed.107.043190. Epub 2008 Apr 15. J Nucl Med. 2008. PMID: 18413376 Free article.

2

High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.

Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF. Rajendran JG, et al. J Nucl Med. 2004 Jun;45(6):1059-64. J Nucl Med. 2004. PMID: 15181141 Free article. Clinical Trial.

3

Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using (131)I tositumomab to that of other types of non-Hodgkin's lymphoma.

Rajendran J, Gopal A, Durack L, Fisher D, Press O, Eary J. Rajendran J, et al. Cancer Biother Radiopharm. 2004 Dec;19(6):738-45. doi: 10.1089/cbr.2004.19.738. Cancer Biother Radiopharm. 2004. PMID: 15665621

4

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA. Wiseman GA, et al. J Nucl Med. 2003 Mar;44(3):465-74. J Nucl Med. 2003. PMID: 12621016 Free article. Clinical Trial.

5

Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.

Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, Peschel C, Schwaiger M. Scheidhauer K, et al. Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1276-82. doi: 10.1007/s00259-002-0820-7. Epub 2002 Jul 6. Eur J Nucl Med Mol Imaging. 2002. PMID: 12271407 Clinical Trial.

6

Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.

Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ. Postema EJ, et al. J Nucl Med. 2003 Oct;44(10):1690-9. J Nucl Med. 2003. PMID: 14530488 Free article. Clinical Trial.

7

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM. Sharkey RM, et al. J Nucl Med. 2003 Dec;44(12):2000-18. J Nucl Med. 2003. PMID: 14660727 Free article. Clinical Trial.

8

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR. Wiseman GA, et al. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94. doi: 10.1016/s1040-8428(01)00107-x. Crit Rev Oncol Hematol. 2001. PMID: 11418315 Clinical Trial.

9

Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.

Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, Larson SM, Zelenetz AD. Sgouros G, et al. J Nucl Med. 2003 Feb;44(2):260-8. J Nucl Med. 2003. PMID: 12571219 Free article. Clinical Trial.

10

A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.

Siegel JA, Kroll S, Regan D, Kaminski MS, Wahl RL. Siegel JA, et al. J Nucl Med. 2002 Mar;43(3):354-63. J Nucl Med. 2002. PMID: 11884495 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

145 results

Results by year